Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly – TheStreet.com
Financial Times |
Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly
TheStreet.com Bristol-Myers Squibb (BMY) suffered another cancer immunotherapy setback Thursday night when the pharma giant said it would not seek accelerated approval for a combination of two drugs — Opdivo and Yervoy — as a treatment for newly diagnosed lung … Bristol-Myers shares slide on immunotherapy setback Bristol-Myers Dives On Opdivo Setback, Will Get Keytruda Royalties Bristol won't seek faster Opdivo/Yervoy lung cancer approval |
